REVENUE - Summary of Analysis of Revenue (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| Other revenue | $ 0.1 | $ 0.0 | $ 0.1 | $ 0.1 | ||
| License and other revenue - total | [1] | 61.4 | 35.4 | 68.1 | 44.8 | |
| Collaboration revenue | 326.1 | 219.7 | 624.5 | 405.3 | ||
| Total revenue | 387.5 | 255.1 | 692.6 | 450.1 | ||
| Novartis | ||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| License revenue | 5.3 | 15.4 | 10.4 | 24.7 | ||
| Janssen | ||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| License revenue | 56.0 | 0.0 | 56.0 | 0.0 | ||
| Related Party Sublicense | ||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| License revenue | $ 0.0 | $ 20.0 | $ 1.6 | $ 20.0 | ||
| ||||||